Left ventricular area on non-contrast cardiac computed tomography as a predictor of incident heart failure The Multi-Ethnic Study of Atherosclerosis

Marcio Sommer Bittencourt, Brigham and Women’s Hospital
Ron Blankstein, Brigham and Women’s Hospital
Songshou Mao, Los Angeles Biomedical Research Institute
Juan J. Rivera, Johns Hopkins Ciccarone Center
Alain G. Bertoni, Wake Forest University
Leslee Shaw, Emory University
Roger S. Blumenthal, Johns Hopkins Ciccarone Center
Matthew J. Budoff, Los Angeles Biomedical Research Institute
Khurram Nasir, Johns Hopkins Ciccarone Center

Journal Title: Journal of Cardiovascular Computed Tomography
Volume: Volume 10, Number 6
Publisher: Elsevier | 2016-11, Pages 500-506
Type of Work: Article | Post-print: After Peer Review
Publisher DOI: 10.1016/j.jcct.2016.07.009
Permanent URL: https://pid.emory.edu/ark:/25593/s6br8

Final published version: http://dx.doi.org/10.1016/j.jcct.2016.07.009

Copyright information:
© 2016 Society of Cardiovascular Computed Tomography

Accessed October 6, 2019 1:50 PM EDT
Left ventricle area on non-contrast cardiac computed tomography as a predictor of incident Heart Failure - The Multi-Ethnic Study of Atherosclerosis

Marcio Sommer Bittencourt, MD MPH PhD1,2,3, Ron Blankstein, MD1, Songshou Mao4, Juan J Rivera5, Alain G Berti, MD MPH6, Leslee J Shaw, PhD7, Roger S Blumenthal, MD5, Matthew J Budoff, MD4, and Khurram Nasir, MD MPH5,8,9,10

1Non-Invasive Cardiovascular Imaging Program, Departments of Medicine (Cardiovascular Division) and Radiology; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
2Center for Clinical and Epidemiological Research, University Hospital, University of São Paulo School of Medicine, São Paulo, Brazil
3Division of Cardiology, São Paulo State Cancer Institute (ICESP), University of São Paulo, São Paulo, Brazil
4Division of Cardiology, Los Angeles Biomedical Research Institute at Harbour-UCLA, Torrance, CA
5The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD
6Department of Epidemiology and Prevention, Wake Forest University School of Medicine, Winston Salem, NC
7Department of Medicine, Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine, Atlanta, GA
8Center for Healthcare Advancement & Outcomes, Baptist Health South Florida, Miami FL
9Miami Cardiac & Vascular Institute (MCVI), Baptist Health South Florida, Miami FL
10Department of Medicine Herbert Wertheim College of Medicine & Department of Epidemiology, Robert Stempel College of Public Health and Social Work, Florida International University, Miami FL

Abstract

Background—The use of non-contrast computed tomography (nCT) measurements to predict heart failure (HF) has not been studied. In the present study we evaluated the prognostic value of
left ventricular area adjusted for the body surface area (LVA-BSA) measured by nCT to predict incident HF and cardiovascular disease (CVD) events.

**Methods**—We studied 6781 participants (mean age: was 62 ± 10 years, 53% females; 62% non-white) free from prior HF in the MESA study who underwent nCT to evaluate left ventricular dimensions and coronary artery calcium score (CAC) at baseline and were followed up for a median of 10.2 years. The LVA-BSA was measured in nCT as previously validated.

**Results**—During follow up, 237 (3.5%) incident HF and 475 (7.0%) CVD events occurred. After adjustment for clinical variables and CAC, the LVA-BSA was significantly associated with incident HF (hazard ratio [HR]: 1.10 per 100 mm$^2$/m$^2$, p<0.001) and CVD events (HR: 1.07 per 100 mm$^2$/m$^2$, p<0.001). The area under the ROC curve for the prediction of incident HF improved from 0.787 on a model including only risk factors to 0.798 when CAC was added (p=0.02), and to 0.816 with the additional inclusion of LVA-BSA (p=0.007). Similar improvement in the prediction of CVD events was noted.

**Conclusion**—In an ethnically diverse population of asymptomatic individuals free from baseline CVD or HF, the left ventricular area measured by nCT is a strong predictor of incident HF events beyond traditional risk factors and CAC score.

**Keywords**
non-contrast cardiac computed tomography; left ventricle size; heart failure; and prognosis

**Introduction**

Heart failure is a major public health problem, accounting for one in every eight deaths in the U. S.$^1$ Current guidelines suggest that early initiation of therapy in asymptomatic at risk individuals is desirable,$^2$ though evidence to support the use of any screening tests for heart failure is scarce.$^3$

Different studies have been used to evaluate the left ventricle as a predictor of events. Early studies using electrocardiography have shown that left ventricular (LV) hypertrophy is associated with CHD,$^4$ LV mass measured by echocardiography was independently associated with CHD and CVD events,$^5$ while cardiac magnetic resonance imaging measures of the LV cavity were independently associated with both CHD and CVD.$^6$ However, due to the significant cost associated with additional screening tests, none of these measures is currently recommended to evaluate asymptomatic individuals. Our group has previously demonstrated that the same non-contrast cardiac computed tomography scan (nCT) used to measure the coronary artery calcium (CAC) score can also be used to estimate the LV size. The nCT derived measurement of the LV has been validated against the gold standard of cardiac magnetic resonance imaging in the same Multi-Ethnic Study of Atherosclerosis (MESA) study cohort, with a correlation of 0.73 with LV volume, 0.74 with LV mass, and 0.79 with LV end-diastolic total volume.$^7$ However, whether measures of the LV size in nCT can improve risk prediction is not known. Thus, in this study we have investigated whether nCT evaluation of LV size can be used to predict incident heart failure and CVD events beyond currently used clinical tools and the coronary artery calcium score.
Methods

The Multi-Ethnic-Study of Atherosclerosis (MESA) is a study designed to evaluate prospectively the development and progression of atherosclerotic disease in a multiethnic population. The full study design has been previously published\(^8\). In brief, the current study included 6814 participants of the MESA study recruited between July 2000 and August 2002. The population studied was between 45 and 84 years old, of both genders, free from any clinically apparent CVD, including HF, and self-reported as one of the four following ethnicities: White, African-American, Hispanic, or Chinese. Participants were recruited in six US communities: Baltimore City and Baltimore County, Maryland; Chicago, Illinois; Forsyth County, North Carolina; Los Angeles County, California; Northern Manhattan and the Bronx, New York; and St. Paul, Minnesota. The institutional review boards at all participating centers approved the study, and all participants gave informed consent.

Clinical profile and risk factor measures

All participants completed an extensive standardized questionnaire to collect information about diabetes, medications used to treat blood pressure and cholesterol, and smoking status. Additionally, participants underwent a clinical and laboratory evaluation as detailed in previously published material.\(^9\) The body surface area (BSA) was calculated by the formula:

\[
\text{BSA (m}^2) = 0.20247 \times \text{ht (m)}^{0.725} \times \text{wt (kg)}^{0.425};
\]

where \(\text{ht}\) is height and \(\text{wt}\) is weight.

Non-contrast computed tomography protocol

MESA participants underwent nCT for coronary calcium score evaluation as previously described\(^10\). Approximately half of the scans were performed with a four row detector CT scanner, while electron beam tomography (EBT) was used for the others. The scan field of view was 35 cm for all scanners, and at least 10.5 cm of data in the \(z\) direction was acquired. The default settings for each scanner were: (1) GE Light Speed: 500-ms rotation time, 120 kVp, 320 mA, \(4 \times 2.5\) mm collimation, sequential axial scans, segmented reconstruction, standard filter; (2) Siemens Volume Zoom: 140 kVp, 50 mAs, (139 mA, 0.361-s scan), \(4 \times 2.5\) mm collimation, sequential axial scans with prospective cardiac gating, standard filter reconstruction; (3) Imatron EBT scanners: 130 kVp, 630 mA, scan time 100 ms, \(3\) mm collimation, sharp reconstruction filter. For EBT scans, prospective electrocardiographic gating was used with scanner triggering at 80% of the R-R interval, while 50% of the cardiac cycle for the multi detectors CT scanners.

CT studies were acquired with a minimum of 40 images of 2.5 to 3 mm slice thickness starting above the left main and extending to the bottom of both ventricles. The determination of the LV area was performed as previously published\(^7\). Briefly, a single midventricular slice was selected according to the natural cardiac markers that include pericardial fat, epicardial fat in the atroventricular groove, and the interventricular groove. The midventricular slice was defined as the level containing the coronary sinus slice or the first level below the left atrium. Second, a straight line connecting the anteroposterior juncture of both ventricles was drawn to divide the left and right ventricles, and the area of the left ventricle was then traced. The anteroposterior juncture origin is the interventricular groove, identified by natural markers such as the abrupt dip, which represents fat tissue or a
high-density circular image, which represent the transverse section image of the left anterior descending coronary artery (figure 1). The LVA was then adjusted to body surface area (LVA-BSA).

**Adjudication of events**

Participants were followed for a median of 10.2 (first quartile: 9.7 – third quartile: 10.7) years for incident HF, CHD and CVD events from their baseline examinations. Follow up consisted of three follow-up visits conducted by each participating center. In addition, participants were contacted by telephone every 9 to 12 months and questioned on hospital admissions, CVD events, deaths and outpatient diagnosis. To adjudicate those events, copies of all medical records for all hospitalizations and outpatient contacts that resulted in new cardiovascular diagnosis as well as death certificates were obtained.

Two independent physicians from the MESA events committee adjudicated every event after review of all medical records. Endpoints were then classified and an incident date was defined. The classification followed strictly pre-defined criteria. In case of discordant review, differences were adjudicated. If differences persisted, the full events committee made a final decision.

Incident HF included both definite and probable HF. Definite and probable HF required clinical symptoms (e.g., shortness of breath) or signs (e.g., edema), because asymptomatic disease was not an endpoint. Probable HF further required a physician diagnosis of HF and medical treatment for HF. Definite HF also required: 1) pulmonary edema/congestion by chest radiograph; and/or 2) dilated ventricle or poor LV function by echocardiography or ventriculography, or evidence of LV diastolic dysfunction. Thus, all HF cases including both cases of HF with preserved as well as reduced ejection fraction were included in the analysis.

CHD events included both myocardial infarction and new episodes of angina. Myocardial infarction was defined as definite, probable or absent based on symptoms, ECG abnormalities and cardiac biomarkers. Coronary artery disease death was classified as present or absent based on review of hospital records and interview of families. A fatal coronary event was defined as a documented myocardial infarction within 28 days of death, chest pain in the 72 hours prior to death or a history of coronary artery disease and no other known non-atherosclerotic or non-cardiac cause for death.

Angina was graded using pre-specified criteria and defined as definite, probable or absent. Probable angina required clearly documented chest pain or angina equivalent. Definite angina was defined by the same criteria, associated with objective evidence of obstructive coronary artery disease or reversible myocardial ischemia.

Overall CVD events included MI, resuscitated cardiac arrest, angina, heart failure, peripheral vascular disease, stroke, and TIA.
Statistical Analysis

All continuous variables are expressed as means ± standard deviation. Categorical variables are presented as absolute values and percentages. Continuous variables were compared using one-way ANOVA and correlation was evaluated using Spearman test, whereas categorical variables were analyzed using chi-square tests.

The primary outcome of the analysis was incident HF, while additional analysis were also performed for the secondary outcomes of CVD and CHD.

Unadjusted Cox proportional hazard ratios were calculated, with LVA-BSA modeled as a continuous variable (per one standard deviation increase), as well as using LVA-BSA as an ordinal variable stratified by quartiles. Additional models, adjusting first for: (1) risk factors (age, gender, ethnicity, diabetes, smoking status, LDL, HDL, triglycerides, systolic and diastolic blood pressure and use of anti-hypertensive and lipid lowering drugs); (2) for risk factors plus coronary artery calcium score and (3) for risk factors, CAC and LVA-BSA were developed. For the third model, CAC was included in the model as a continuous ln of CAC + 1 to correct for the asymmetrical distribution of CAC valued. To evaluate the possible interaction between calcium score and LVA, an interaction term was added to the model. However, results for interactions were not presented unless significant. Nelson Aalen events curves were constructed for the primary and secondary outcomes using LVA-BSA as an ordinal variable stratified by quartiles. Moreover, we derived gender specific quartiles and constructed gender specific curves presented as supplemental material. Additionally, we have calculated the sensitivity and specificity of various LVA-BSA cut-offs for the prediction of incident HF stratified by gender. To compare different multivariable models, the area under the ROC curves were calculated and compared for each of the primary and secondary outcomes.

All analyses were performed using Stata 13.0 for Windows (StataCorp, College Station, Texas). Two-tailed p-values <0.05 were considered statistically significant and presented for descriptive purposes. Confidence intervals are expressed as 95% confidence intervals (CI).

Results

Baseline Characteristics

Among 6814 MESA participants, 6781 had complete clinical and follow up information for all outcomes and were included in the present analysis. The mean LVA was 4018±734 mm², and the LVA-BSA had a mean of 2158±310 mm² per m². The first quartile of LVA-BSA had a range from 1200 to 1946 mm² per m², the second quartile from 1947 to 2138, the third quartile from 2139 to 2342 mm² per m² and the 4th quartile from 2343 to 2724 mm² per m².

Among the baseline characteristics, male gender, non-white race, no prior smoking history, diabetes, hypertension, elevated systolic and diastolic blood pressure and use of anti-hypertensive therapy were significantly associated with LVA-BSA. Family history of coronary heart disease, BMI, HDL and use of lipid lowering medication were all inversely associated with LVA-BSA. (Table 1).
Incident Events

During follow-up, there were 639 (9.4%) CVD events, including 449 (6.6%) incident CHD events and 237 (3.5%) incident HF cases. The number of events according to the LVA-BSA quartiles are presented in table 1.

Univariable Predictors of Heart Failure Events

Incident HF was associated with increased age, male gender, prior history of smoking, elevated systolic and diastolic BP, BMI and use of anti-hypertensive medications, while Chinese race was associated with a lower HF incidence when compared to white (table 2).

Higher CAC scores and higher LVA-BSA (p<0.001) were also significantly associated with incident HF in the univariable analysis (table 2).

LVA-BSA as a predictor of events

The incidence of HF in the first LVA-BSA quartile was 2.26 (95%CI: 1.63 – 3.12) events per 1000 person years, for the second, third and fourth quartiles the rates were 2.50 (95%CI: 1.84 – 3.41), 3.38 (95%CI: 2.59 – 4.42) and 6.94 (95%CI: 5.74 – 8.39), respectively (p<0.001, figure 2A). LVA-BSA was also a significant predictor for the secondary outcomes of CVD and CHD (p<0.001 for both, figures 2B and 2C). A similar pattern was noted when the data was stratified by gender, and gender specific quartile were used, however, the incidence of events was lower in women (supplemental figures 1–3). Additionally, we have calculated the sensitivity and specificity of a range of LVA-BSA values for the prediction of incident HF stratified by gender (supplemental table 1).

LVA-BSA and CAC as predictors of events

A stepwise increase in the incidence of HF for each CAC level was noted across the spectrum of LVA-BSA (p<0.001), though no significant interaction between the two was noted (figure 3A). A similar pattern was noted for the secondary outcomes of CHD and CVD (p<0.001, figures 3B and 3C).

Multivariable models for the prediction of events

Even after adjustment for all risk factors and ln (CAC+1), the LVA-BSA remained a significant predictor of incident heart failure with a hazard ratio (HR) of 1.15 (95%CI: 1.11 – 1.20, p<0.001) per 100 mm²/m² increase. Similarly, LVA-BSA remained a significant predictor of future CHD events with a HR of 1.07 (95%CI: 1.03 – 1.10, p<0.001) per one standard deviation increase, of future hard CHD events with a HR of 1.29 (95%CI: 1.15 – 1.46), and of future CVD events, with a hazard ratio of 1.07 per 100 mm²/m² increase. (95%CI: 1.04 – 1.10, p<0.001).

Improvement in prediction models

For the primary outcome of HF, the inclusion of the ln(CAC+1) to a model containing all clinical risk factors (model 1) resulted in a significant improvement in the area under the ROC curve from 0.787 to 0.799, p=0.01. Additionally, the inclusion of LVA-BSA resulted in
an even further improvement in discrimination beyond the model including all risk factor plus CAC score, from 0.799 to 0.816, p=0.01 (figure 4A).

For the secondary outcome of CHD, the inclusion of CAC score to the baseline model resulted in a significant increase in the area under the ROC curve from 0.743 to 0.795, p<0.001. The inclusion of LVA-BSA in a model containing risk factors and CAC score resulted in a small change in the area under the ROC curve which did not reach statistical significance (0.795 to 0.799, p-value not significant) (figure 4B).

For the secondary outcome of CVD, the inclusion of CAC score to the baseline model also resulted in a significant increase in the area under the ROC curve from 0.747 to 0.782, p<0.001. The inclusion of LVA-BSA in a model containing risk factors and CAC score resulted in a small but significant increase in the area under the ROC curve from 0.782 to 0.786, p-value not significant (figure 4C).

Discussion

Our study has demonstrated that a nCT performed to measure the CAC score also allows for measurement of the left ventricular size. This measurement is an independent predictor of incident heart failure and cardiovascular disease events as a whole. The inclusion of this measure in a model containing risk factors and CAC results in improved discrimination for heart failure. Our results demonstrate that this simple measure of LV size (which takes ~1 minute to measure and does not require any changes to current acquisition protocols) adds prognostic value even when a well-validated and powerful predictor of coronary events (i.e. CAC) is already included in the model.

Other studies have previously evaluated other measures of LV size as predictors of CHD, CVD and HF in asymptomatic individuals. Initial data from the Framingham study demonstrated that LV hypertrophy evaluated by ECG was associated with a 2 to 3-fold in the incidence of CHD. While more recent data with more appropriate adjustment for confounding has also suggested a relative risk of 2.3 for the presence of LV hypertrophy on the ECG, though a study by Mazza et al has shown that LVH detected on ECG has only a relative risk of 1.4 for the prediction of HF mortality. Others, however, have suggested that the clinical implications of ECG might be limited due to an extremely low sensitivity when compared to echocardiography.

The prognostic importance of LV size has also been evaluated in prior imaging studies using echocardiography and magnetic resonance imaging. A classical echocardiography study has demonstrated that LV mass is directly associated with increased CVD and mortality, while more recent data has demonstrated that LV mass, lower ejection fraction and diastolic dysfunction are associated with combined CVD events including HF.

A prior analysis from the MESA cohort has shown that LV mass and volume measured by magnetic resonance are both independently associated with CHD, CVD and HF. In these studies, extreme values of LV mass above the 95th percentile were the best predictors of HF, with an adjusted HR of 8.6. Interestingly, none of the other LV measures, such as LV mass to LV volume, were significantly associated with HF. Based on this, the authors proposed...
that the events were primary driven by the increase in LV mass. Our data, however, found that LV size was a significant predictor for all events. Even if the LV mass is the primary driver for events, as previously proposed, our data supports the use of LV size measured by nCT is an adequate surrogate marker of more precise LV measurements in the risk stratification of asymptomatic individuals. In fact, although nCT images are static and the lack of contrast does not allow for measurement of LV wall thickness, the measurement of the LV size measured by nCT is accurate and reproducible. Although the LV size measure on nCT has not been broadly studied, one recent publication has analyzed the predictive value of this measurement on CVD, and their results are comparable to the present data. However, their study was limited to CV events, and no data on heart failure was available.

Since this information adds no additional cost or risk, it could easily be incorporated on clinical reports of CAC scans performed for routine clinical indications. Although no studies are currently indicated as screening methods for HF, current guidelines recommend interventions to prevent overt symptomatic HF in individuals of increase risk, even though at present such individuals would only be identified based on clinical characteristics.

A secondary finding of our study was that CAC is an independent predictor of HF. Although there is evidence suggesting that CAC is associated with prevalent HF and with NT-pro-BNP, no previous evidence that CAC can adequately predict incident HF was available. This finding is not unexpected, as about half of all incident cases of HF are caused by CHD. Nevertheless, no prior evidence that CAC was an independent predictor of incident heart failure exists. Lastly, the association of CAC and LV-BSA provided complementary information for the prediction of both CHD and HF.

Although there is no data on strategies using LV size or CAC to identify and potentially treat individuals at risk for HF, our results suggest that the measurement of the LVA-BSA and CAC provides incremental value to predict HF. If an nCT is performed for other clinical indications, such as the evaluation of CAC for primary prevention, the measurement of LV size may help identify individuals at risk for the development of HF. Those asymptomatic individuals, who would otherwise not be investigated, could then be refereed for a more refined assessment of LV structure and function with echocardiography. However, future studies should evaluate whether this measurement can be used effectively to identify subgroups of patients who may benefit from interventions aimed at reducing the risk of incident HF. Even if such strategies are proven to be clinically relevant, its cost-effectiveness implications would need to be evaluated prior to routine use.

Our study has several limitations. First, the traced area of the LV comprises both the cavity and the myocardial wall. Therefore, differentiating dilated from hypertrophic cardiomyopathies is not possible. Consequently, our method cannot be recommended as a tool to estimate the left ventricular function or wall thickness. However, it may work well as a screening tool for pre-clinical LV abnormalities. While we do not suggest that nCT should be used for routine screening of asymptomatic individuals for HF as this is not currently recommended for the general population, the additional information of LV size estimation by nCT might be of clinical interest in individuals who undergo a nCT for other reasons such as the CVD risk stratification with a CAC. Second, the appearance of the LV on an
axial non-contrast study has variability and thus the size estimation may lack precision in patients who have a distorted LV geometry. Another potential source for variability is that tracing of the interventricular septum can be challenging. Third, if only regional changes in LV geometry are present without adverse remodeling, the overall LV size may be preserved. However, such scenarios are far more common in the presence of prior MI or CHD, which is likely to be clinically known. Despite the aforementioned technical challenges, the LVA-BSA measures are consistent predictors of events in our study. Fourth, the definition of HF in epidemiological studies rely on the data and tests at the time of diagnosis. Thus, limitations on the performance of diagnostic tests, such as echocardiograms or other measurement of left ventricular function may have influence the definition of events. However, this approach is the standard in most cohort studies due to the limitation of collecting data after the event has already occurred. Additionally, our study included both electron beam and multidetector nCT, which were performed under different protocols. Those differences in protocols may have resulted in variability in the LVA measurements. Thus, the actual values reported here may not be valid under different CT protocols. Finally, individuals with right heart dysfunction or heart failure with preserved ejection fraction may develop clinical symptoms of HF in the absence of any changes to LV dimensions. However, the inability to identify such cases by our methods of estimating LV size would only weaken its association with incident HF.

The results of our study show that LVA-BSA is a strong predictor of incident HF among asymptomatic individuals, which is incremental to traditional risk factors and to CAC. Therefore, we propose that this simple measure should be included as part of the nCT exam for all individuals who undergo CAC testing to further assess their HF and cardiovascular risk. Although no specific intervention to prevent or delay the presentation of HF in this population has been tested yet, individuals on the fourth quartile in our study may be referred to a clinical evaluation to review and treat any modifiable risk factor for HF. Selected individuals might also benefit from additional evaluation with echocardiography or cardiac MRI. Such an approach may allow for earlier identification of individuals at risk for heart failure, allowing early initiation of appropriate therapies, which may halt the progression of the disease. Importantly, among individuals referred for CAC testing, the screening approach proposed above would only require 1 additional minute of analysis (and likely far less once this measurement can be automated using currently used image interpretation software) at no additional cost or radiation. However, it is noteworthy, that nCT is not recommended solely for evaluating the LV size.

Conclusions

In an ethnically diverse population of asymptomatic individuals free from any baseline CVD or HF, the LV area measured by nCT is associated with incident HF events. This association is independent from and complementary to clinical risk factors and CAC score.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.
Acknowledgments

This research was supported by contracts N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168 and N01-HC-95169 from the National Heart, Lung, and Blood Institute and by grants UL1-TR-000040 and UL1-TR-001079 from NCRR. The authors thank the other investigators, the staff, and the participants of the MESA study for their valuable contributions. A full list of participating MESA investigators and institutions can be found at http://www.mesa-nhlbi.org.

References


Figure 1. Example of the LVA measurement

The antero-posterior juncture origin is the interventricular groove, identified by the natural markers, such as the abrupt dip that represents fat tissue. The lateral border is easily identified by the abrupt change in contrast density from the cardiac silhouette to the pericardial fat. The posterior reference is the atrioventricular groove. A straight line connecting the antero-posterior juncture of both ventricles is drawn to complete the tracing (red line).
Figure 2. Nelson-Aalen curves stratified by LVA-BSA quartiles

A: Cumulative incidence curves for incident HF. B: Cumulative incidence curves for incident coronary heart disease (CHD). C: Cumulative incidence curves for incident cardiovascular disease (CVD) events.
Figure 3. HF, CHD and CVD event rates according to CAC categories and LVA-BSA quartiles
A: Incidence rate of HF per 1000 person years. B: Incidence rate of CHD per 1000 person years. C: Incidence rate of CVD per 1000 person years.
Receiver Operator Characteristics (ROC) curves for the prediction of Heart Failure

- Risk factors (ROC area: 0.787)
- Risk factors + In(CAC+1) (ROC area: 0.799)
- Risk factors + In(CAC+1) + LVA-BSA (ROC area: 0.818)

p=0.01
Receiver Operator Characteristics (ROC) curves for the prediction of coronary heart disease

- Risk factors (ROC area: 0.743)
- Risk factors + ln(CAC+1) (ROC area: 0.795)\[ p<0.001 \]
- Risk Factors + ln(CAC+1) + LVA-BSA (ROC area: 0.799)\[ p=NS \]
Figure 4. ROC curves of to predict HF (panel A), CHD (panel B) and CVD (panel C)

The blue line represents a model based on clinical variables only. The red line includes the clinical model plus the calcium score, whereas the green line also includes the LVA-BSA. The clinical model includes age, gender, race, and smoking status, family history of coronary heart disease, history of diabetes, history of hypertension, systolic and diastolic blood pressure, LDL, HDL, BMI, use of anti-hypertensive medication and use of lipid lowering medication.
<table>
<thead>
<tr>
<th>Variable</th>
<th>LVA-BSA 1st quartile</th>
<th>LVA-BSA 2nd quartile</th>
<th>LVA-BSA 3rd quartile</th>
<th>LVA-BSA 4th quartile</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population size</td>
<td>1697</td>
<td>1693</td>
<td>1697</td>
<td>1694</td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>62.3±10.1</td>
<td>62.2±10.1</td>
<td>61.5±10.3</td>
<td>62.5±10.4</td>
<td>0.03</td>
</tr>
<tr>
<td>Men (%)</td>
<td>629 (37%)</td>
<td>732 (43%)</td>
<td>821 (49%)</td>
<td>1009 (60%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Race (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>White</td>
<td>878 (52%)</td>
<td>700 (42%)</td>
<td>583 (35%)</td>
<td>441 (26%)</td>
<td></td>
</tr>
<tr>
<td>Hispanic</td>
<td>268 (16%)</td>
<td>326 (19%)</td>
<td>411 (24%)</td>
<td>489 (29%)</td>
<td></td>
</tr>
<tr>
<td>African-American</td>
<td>415 (24%)</td>
<td>463 (27%)</td>
<td>479 (28%)</td>
<td>507 (30%)</td>
<td></td>
</tr>
<tr>
<td>Chinese</td>
<td>130 (8%)</td>
<td>200 (12%)</td>
<td>214 (13%)</td>
<td>257 (15%)</td>
<td></td>
</tr>
<tr>
<td>Smoking (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Never</td>
<td>791 (47%)</td>
<td>852 (50%)</td>
<td>866 (51%)</td>
<td>893 (53%)</td>
<td></td>
</tr>
<tr>
<td>Former</td>
<td>661 (39%)</td>
<td>641 (38%)</td>
<td>620 (37%)</td>
<td>555 (33%)</td>
<td></td>
</tr>
<tr>
<td>Current</td>
<td>239 (14%)</td>
<td>196 (12%)</td>
<td>201 (12%)</td>
<td>246 (14%)</td>
<td></td>
</tr>
<tr>
<td>Family history of CHD (%)</td>
<td>735 (46%)</td>
<td>677 (43%)</td>
<td>682 (43%)</td>
<td>617 (39%)</td>
<td>0.001</td>
</tr>
<tr>
<td>Diabetes (%)</td>
<td>132 (8%)</td>
<td>145 (9%)</td>
<td>172 (10%)</td>
<td>209 (12%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Hypertension (%)</td>
<td>615 (36%)</td>
<td>708 (42%)</td>
<td>779 (46%)</td>
<td>929 (55%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Systolic BP (mmHg)</td>
<td>122±19</td>
<td>125±21</td>
<td>126±21</td>
<td>132±28</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Diastolic BP (mmHg)</td>
<td>70±10</td>
<td>71±10</td>
<td>72±10</td>
<td>74±10</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>28.8±6.2</td>
<td>28.6±5.6</td>
<td>28.2±5.1</td>
<td>27.7±4.7</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>LDL (mg/dL)</td>
<td>117±32</td>
<td>118±32</td>
<td>117±31</td>
<td>116±31</td>
<td>0.5</td>
</tr>
<tr>
<td>HDL (mg/dL)</td>
<td>52±15</td>
<td>51±15</td>
<td>51±15</td>
<td>50±14</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Triglycerides (mg/dL)</td>
<td>131±78</td>
<td>133±79</td>
<td>134±108</td>
<td>129±87</td>
<td>0.51</td>
</tr>
<tr>
<td>Anti-hypertensive therapy (%)</td>
<td>547 (32%)</td>
<td>584 (35%)</td>
<td>645 (38%)</td>
<td>735 (43%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Lipid lowering therapy (%)</td>
<td>315 (19%)</td>
<td>279 (17%)</td>
<td>265 (16%)</td>
<td>234 (14%)</td>
<td>0.002</td>
</tr>
<tr>
<td>Variable</td>
<td>LVA-BSA 1&lt;sup&gt;st&lt;/sup&gt; quartile</td>
<td>LVA-BSA 2&lt;sup&gt;nd&lt;/sup&gt; quartile</td>
<td>LVA-BSA 3&lt;sup&gt;rd&lt;/sup&gt; quartile</td>
<td>LVA-BSA 4&lt;sup&gt;th&lt;/sup&gt; quartile</td>
<td>P</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>----------------------------------</td>
<td>----------------------------------</td>
<td>----------------------------------</td>
<td>----------------------------------</td>
<td>---------</td>
</tr>
<tr>
<td>Coronary Artery Calcium Score</td>
<td>124±333</td>
<td>130±240</td>
<td>138±435</td>
<td>191±527 &lt;0.001</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Events</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heart Failure</td>
<td>37 (2.2%)</td>
<td>40 (2.4%)</td>
<td>54 (3.2%)</td>
<td>106 (6.2%)</td>
<td></td>
</tr>
<tr>
<td>CHD events</td>
<td>95 (5.6%)</td>
<td>100 (5.9%)</td>
<td>102 (6.0%)</td>
<td>152 (8.9%)</td>
<td></td>
</tr>
<tr>
<td>Cardiovascular events</td>
<td>131 (7.7%)</td>
<td>143 (8.4%)</td>
<td>148 (8.7%)</td>
<td>217 (12.8%)</td>
<td></td>
</tr>
</tbody>
</table>

Values are mean ± SD, median (interquartile range), or n (%).

BMI= body mass index, BP= blood pressure, CHD: coronary heart disease, HDL= high-density lipoprotein, LDL= low-density lipoprotein.
Table 2
Univariate Cox proportional Hazard ratios for the prediction of heart failure.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Heart Failure</th>
<th>HR</th>
<th>95% CI</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (per 10 years)</td>
<td></td>
<td>2.08</td>
<td>1.81 – 2.38</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Men (%)</td>
<td></td>
<td>1.63</td>
<td>1.26 – 2.12</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Race (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td></td>
<td>Ref</td>
<td>Ref</td>
<td>Ref</td>
</tr>
<tr>
<td>Hispanic</td>
<td></td>
<td>0.98</td>
<td>0.69 – 1.38</td>
<td>0.89</td>
</tr>
<tr>
<td>African-American</td>
<td></td>
<td>1.22</td>
<td>0.91 – 1.65</td>
<td>0.19</td>
</tr>
<tr>
<td>Chinese</td>
<td></td>
<td>0.49</td>
<td>0.28 – 0.86</td>
<td>0.01</td>
</tr>
<tr>
<td>Smoking (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Never</td>
<td></td>
<td>Ref</td>
<td>Ref</td>
<td>Ref</td>
</tr>
<tr>
<td>Former</td>
<td></td>
<td>1.41</td>
<td>1.08 – 1.87</td>
<td>0.01</td>
</tr>
<tr>
<td>Current</td>
<td></td>
<td>1.42</td>
<td>0.97 – 2.09</td>
<td>0.07</td>
</tr>
<tr>
<td>Family history of CHD (%)</td>
<td></td>
<td>1.24</td>
<td>0.95 – 1.62</td>
<td>0.11</td>
</tr>
<tr>
<td>Diabetes (%)</td>
<td></td>
<td>3.76</td>
<td>2.82 – 50.2</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Hypertension (%)</td>
<td></td>
<td>3.57</td>
<td>2.66 – 4.72</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Systolic BP (per 10 mmHg)</td>
<td></td>
<td>1.27</td>
<td>1.21 – 1.34</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Diastolic BP (per 10 mmHg)</td>
<td></td>
<td>1.17</td>
<td>1.04 – 1.32</td>
<td>0.01</td>
</tr>
<tr>
<td>BMI (per 10 kg/m²)</td>
<td></td>
<td>1.60</td>
<td>1.30 – 1.96</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>LDL (per 10 mg/dL)</td>
<td></td>
<td>0.96</td>
<td>0.92 – 1.00</td>
<td>0.06</td>
</tr>
<tr>
<td>HDL (per 10 mg/dL)</td>
<td></td>
<td>0.88</td>
<td>0.80 – 0.97</td>
<td>0.009</td>
</tr>
<tr>
<td>Triglycerides (per 10 mg/dL)</td>
<td></td>
<td>1.01</td>
<td>0.99 – 1.02</td>
<td>0.06</td>
</tr>
<tr>
<td>Anti-hypertensive therapy (%)</td>
<td></td>
<td>2.82</td>
<td>2.18 – 3.67</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Lipid lowering therapy (%)</td>
<td></td>
<td>1.33</td>
<td>0.97 – 1.83</td>
<td>0.08</td>
</tr>
<tr>
<td>Coronary Artery Calcium Score</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td></td>
<td>Ref</td>
<td>Ref</td>
<td>Ref</td>
</tr>
<tr>
<td>1 – 100</td>
<td></td>
<td>1.54</td>
<td>1.06 – 2.23</td>
<td>0.02</td>
</tr>
<tr>
<td>&gt;100</td>
<td></td>
<td>4.72</td>
<td>3.49 – 6.40</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>LVA-BSA (per 100 mm²/m²)</td>
<td></td>
<td>1.17</td>
<td>1.14 – 1.20</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

BMI= body mass index, BP= blood pressure, CHD: coronary heart disease, HDL= high density lipoprotein, LDL= low density lipoprotein, LVA-BSA.